8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

______________________

Date of Report (Date of earliest event reported):  March 19, 2010

THE QUIGLEY CORPORATION

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation) 0-21617 (Commission File Number) 23-2577138 (I.R.S. Employer Identification No.)

Kells Building, 621 Shady Retreat Road, P.O. Box 1349 Doylestown, PA	18901
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (215) 345-0919

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On March 19, 2010, The Quigley Corporation (the “Corporation”) issued a press release announcing that it will release its fourth quarter and full year 2009 financial results on March 25, 2010, prior to the opening of the stock market, and will host a conference call at 11:00 AM Eastern Time on March 25, 2010.  A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Additionally, the Corporation issued a press release on March 23, 2010, announcing that on March 22, 2010, the Corporation entered into a joint venture with Phosphagenics Limited to develop a wide range of non-prescription remedies for worldwide distribution and sale.  A copy of the press release is furnished as Exhibit 99.2 to this Form 8-K.

The information in this report, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.	Description
99.1	Press Release dated March 19, 2010
99.2	Press Release dated March 23, 2010

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

The Quigley Corporation
By:	/s/ Robert V. Cuddihy, Jr.
	Robert V. Cuddihy, Jr. Chief Operating Officer

Date: March 23, 2010

EXHIBIT INDEX

No.	Description
99.1	Press Release dated March 19, 2010
99.2	Press Release dated March 23, 2010

EX-99.1

The Quigley Corporation To Release Fourth Quarter Results on Thursday March 25th

DOYLESTOWN, Pennsylvania – March 19, 2010. The Quigley Corporation (Nasdaq: QGLY) announced today that financial results for the fiscal 2010 fourth quarter, ended December 31, 2009, will be released before the market opens on Thursday, March 25, 2010. An earnings conference call will be held later that morning at 11:00 AM.  Quigley’s Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a Company overview including a review of activities and fourth quarter and year-end results. There will be a question and answer session following initial remarks.

The conference call will be webcast live at http://event.meetingstream.com/r.htm?e=201053&s=1&k=FB759E9EF564864738AF09E742BEC903  at 11:00 AM (EST) on Thursday, March 25, 2010.

Participants wishing to ask questions may access the live call by dialing (877) 217-6026 conference ID# 64226162. A replay of the conference call will be available for 90 days on the Company web site at www.quigleyco.com.

About The Quigley Corporation

The Quigley Corporation  is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries including Quigley Manufacturing Inc., which consists of an FDA approved facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities, and Quigley Pharma, Inc., which conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.   For more information visit us at www.Quigleyco.com.

For more information, visit The Quigley Corporation at www.quigleyco.com. 

CONTACT

Media Relations

The Lexicomm Group

Wendi Tush

Wendi@lexicommgroup.com

(212) 794-4531

Lindsey Gardner

Lindsey@lexicommgroup.com

(570) 479-4895

Investor Relations

Ted Karkus

Chairman of the Board, CEO

(215) 345-0919 x0

EX-99.2

March 23, 2010

THE QUIGLEY CORPORATION AND PHOSPHAGENICS LIMITED FORM JV TO DEVELOP AND MARKET OTC PRODUCTS

Phusion Laboratories LLC to leverage Phosphagenics’ TPM™ platform technology with Quigley’s robust distribution network and OTC market expertise

DOYLESTOWN, Pennsylvania – March 23, 2010. The Quigley Corporation (NASDAQ: QGLY) and Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) today announced the formation of a joint venture to develop a wide range of non-prescription remedies for worldwide distribution and sale.

The joint venture entity is the newly formed Phusion Laboratories LLC.   Phusion combines Phosphagenics’ state-of-the-art science and research team with Quigley’s robust distribution network and OTC market expertise to develop and market powerful OTC products.

The new products will be powered by Phosphagenics’ proprietary, patented TPM™ technology.  TPM™ is a patient-friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.  The ability of TPM™ delivery technology to increase the amount and depth of penetration of active molecules into the skin has been compellingly demonstrated in human clinical trials.  It is effective in delivering OTC molecules orally, topically and via inhalation. 

“Phosphagenics’ extraordinary technology lends itself perfectly to delivery of OTC drugs as the inclusion of TPM™ will increase the absorption and efficacy of many OTC active ingredients,” said Quigley CEO Ted Karkus.  “Our signature product Cold-EEZE® has built its reputation and robust distribution network on its uniquely effective delivery system.   We see the world-class scientific research team at Phosphagenics as the perfect partner to help us leverage our existing network and consumer product expertise.”

Harry Rosen, CEO of Phosphagenics, said, “Phosphagenics has invested more than nine years in developing its proprietary TPM™ technology.   Quigley has a proven track record of distributing its OTC lines throughout the US. We see extraordinary OTC products coming out of this joint venture for large markets such as acne treatment and smoking cessation where irritation is a major issue. Our technology has demonstrated that it can deliver products more effectively than other commercial products, while significantly reducing irritation. We believe our partner has an exceptional ability to effectively market and distribute these potential future products.”

“Because we are focusing on OTC drugs, for which no prescription is required, we will avoid the tens of millions of dollars of costs and years of development associated with launching a new prescription drug,” added Mr. Karkus.

Under the terms of the agreement, Quigley and Phosphagenics will each own 50% of Phusion Laboratories, LLC.  Phusion has been granted a worldwide, exclusive, royalty-free license to the TPM™ technology for use in a wide range of non-prescription products, applications and active ingredients.  Quigley will make a one time payment to Phosphagenics of $1 million and the issuance to Phosphagenics of 1.44 million shares of Quigley common stock.

Additionally, Quigley has contributed $500,000 of initial capital and committed up to $2 million toward the initial development and marketing costs of new products for Phusion Laboratories to commercialize.  Phosphagenics will conduct and oversee much of the product development, formulation, testing and other R&D needed by the company.  Quigley will oversee much of the distribution, sales and marketing.

Ted Karkus will discuss and answer questions about Phusion Laboratories during Quigley’s earnings conference call later this week on Thursday, March 25th at 11:00am EDT.

About The Quigley Corporation

The Quigley Corporation is a diversified natural health medical science company.  It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.  The Quigley Corporation has several wholly owned subsidiaries including Quigley Manufacturing Inc., which consists of an FDA approved facility to manufacture Cold-EEZE lozenges and fulfil other contract manufacturing opportunities, and Quigley Pharma, Inc., which conducts research in order to develop and commercialise a pipeline of patented botanical and naturally derived potential prescription drugs.   For more information visit us at www.Quigleyco.com

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. The company is commercializing drug delivery applications based on its novel transdermal (drugs administered via skin) TPM – Targeted Penetration Matrix technology. TPM™ is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

Two product targets are advancing through clinical trials, including an insulin patch for diabetics and an oxycodone patch for the relief of chronic pain.

Phosphagenics’ shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

For more information, visit us at www.phosphagenics.com

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement.  Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

For Quigley:                                                                                                                      

Media Relations

The Lexicomm Group

Wendi Tush

Wendi@lexicommgroup.com

(212) 794-4531

Lindsey Gardner

Lgardner651@gmail.com

(570) 479-4895

www.lexicommgroup.com

Investor Contact

Ted Karkus

Chairman and CEO

The Quigley Corporation

(215) 345-0919 x 0

For Phosphagenics Limited:

Fred Banti, President, Phosphagenics (US)

Phone:  646-706-2155 

Investor and Media Contact:

Michael D. Becker, President & CEO

MD Becker Partners LLC

Phone:  267-756-7094 

Email: michael@mdbpartners.com

Web: www.mdbpartners.com